

## AGENDA

### Friday, October 21, 2022

| TIME    | PRESENTATION  | SPEAKER(S)          |
|---------|---|---------------------|
| 7:00 AM | Registration and Breakfast  |                     |
| 8:00 AM | <a href="#">Welcome</a>   | Sheetal Shroff, MD  |
| 8:10 AM | <a href="#">Overview of Myasthenia Gravis</a>   | Sheetal Shroff, MD  |
| 8:50 AM | Q & A Discussion  |                     |
| 9:00 AM | <a href="#">Management of Acute Exacerbations and Crisis from the Perspective of the Health Care Provider</a> | Ashley Anderson, MD |
| 9:30 AM | Q & A Discussion  |                     |
| 9:40 AM | BREAK   |                     |
| 10:00AM | <a href="#">Current and Future Treatments Myasthenia Gravis</a>   | Amanda Guidon, MD   |
| 11:00AM | Q & A Discussion  |                     |
| 11:30AM | <a href="#">Adjournment</a>   |                     |

### Saturday, October 22, 2022

| TIME    | PRESENTATION  | SPEAKER(S)          |
|---------|---|---------------------|
| 7:00 AM | Registration and Breakfast  |                     |
| 8:00 AM | <a href="#">Welcome</a>   | Sheetal Shroff, MD  |
| 8:05 AM | <a href="#">Overview of Myasthenia Gravis</a>                               | Sheetal Shroff, MD  |
| 8:35 AM | Q & A Discussion  |                     |
| 8:45 AM | <a href="#">Management of Acute Exacerbations and Crisis</a>                | Ashley Anderson, MD |
| 9:15 AM | Q & A Discussion  |                     |
| 9:25 AM | Respiratory Issues in Myasthenic Disease and Management                     | Michelle Cao, MD    |
| 10:00AM | Q & A Discussion  |                     |
| 10:10AM | BREAK   |                     |
| 10:30AM | Navigating the ER: From the perspective of the ER physician and Neurologist | Amanda Guidon, MD   |
| 11:00AM | Q & A Discussion  |                     |
| 11:10AM | <a href="#">Current and Future Treatments Myasthenia Gravis</a>             | Ericka Greene, MD   |
| 11:40AM | Q & A Discussion  |                     |
| 12:00PM | <a href="#">Adjournment</a>   |                     |

**Click the link of the presentation to view the slides (PDF)\*.**

*Slides are posted as they become available. Some slides may not be posted. Refresh this link to check for updates. Links not showing? We suggest trying another browser or downloading this pdf and open with a pdf viewer.*

## FACULTY

### COURSE DIRECTORS

---

#### **Ericka Green, MD, FAAN**

The Sumner Family Chair in Neuromuscular Research, Stanley H. Appel  
Department of Neurology  
Professor of Clinical Neurology, Academic Institute  
Associate Clinical Member, Research Institute  
Program Director, Neurology Residency and Neuromuscular Medicine  
Residency, Stanley H. Appel Department of Neurology  
Houston Methodist  
Weill Cornell Medical College

#### **Sheetal Shroff, MD**

Assistant Professor of Clinical Neurology, Academic Institute  
Assistant Clinical Member, Research Institute  
Houston Methodist  
Weill Cornell Medical College

### GUEST FACULTY

---

#### **Michelle Cao, MD**

Neurology & Neurological Sciences Clinical Associate Professor  
Psychiatry and Behavioral Sciences- Stanford Center for Sleep Sciences  
and Medicine

#### **Amanda Guidon, MD**

Assistant Professor of Neurology, Harvard Medical School  
Program Director, Partners Neuromuscular Medicine Fellowship  
Director, MGH Myasthenia Gravis Clinic  
Massachusetts General Hospital

### HOUSTON METHODIST FACULTY

---

#### **Ashley Anderson, MD, MPH**

Neuromuscular Medicine, Neurology  
Neuromuscular Clinic  
Houston Methodist Stanley H. Appel Department of Neurology

### Friday, October 21, 2022 – Health Care Professionals

#### PROGRAM OVERVIEW

To familiarize health care professionals including neurologist, and non-neurologists regarding clinical presentations and evaluation of patients with acquired neuromuscular junction disorders, including myasthenia gravis, Lambert Eaton myasthenic syndrome in order to enable care providers the ability to diagnosis and manage the myasthenic patient in the acute and ambulatory care settings and minimize disease morbidity and mortality.

#### TARGET AUDIENCE

Emergency medicine physicians, ophthalmologists, internal medicine, pulmonologist, general neurologist, neuromuscular neurologists, anesthesiologists, RN, NPs, PA's and allied health professionals (RT's, Speech therapists, Social work, EMT)

#### EDUCATIONAL OBJECTIVES

At the conclusion of this activity, the participant should be able to:

- Explain the clinical presentations and progression of myasthenic syndromes and associated comorbidities
- Discuss current and emerging therapies for the symptomatic and disease treatment of these disorders
- Describe emerging therapies and research outcomes for these and related disorders
- Apply a working algorithm to facilitate more effective management of the patient

#### NURSING OUTCOMES STATEMENT

Nurses attending this activity will be able to describe clinical signs and symptoms and apply this to nurse decision-making related to the care of the myasthenia Gravis patient as evidenced by a self-reported change in practice on the program evaluation and declaration of at least one learning He/she will apply to their practice.

#### EDUCATION METHODS

Didactic lectures, panel discussion

#### EVALUATION METHOD

Evaluation by questionnaire will address program content, presentation, and possible bias.

### Saturday, October 22, 2022 – Patients and Caregivers

#### PROGRAM OVERVIEW

To provide an overview of acquired autoimmune myasthenia gravis to affected patients, patient family and care providers in order to provide patient ability to self-advocate for appropriate treatment and management by their health care professionals and within the system of medicine and research. In addition, the conference is to provide an opportunity for networking among patients for community support and formal advocacy.

#### TARGET AUDIENCE

Patients with MG, family members, care providers, friends of MG patients. Allied health professionals including SW, RT, OT, PT, speech therapy.

#### EDUCATIONAL OBJECTIVES

At the conclusion of this activity, the participant should be able to:

- Explain the clinical presentations and progression of myasthenia gravis and associated comorbidities
- Discuss current therapies for the symptomatic and disease treatment of these disorders
- Describe emerging therapies and research outcomes for these disorders

- Discuss the respiratory evaluation and management of myasthenia gravis and provide recommendations to effectively access appropriate medical care in the acute setting
- Provide opportunity for networking and exchange of information among patients and promote advocacy within the MG patient community

## ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

### **Physicians**

Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Houston Methodist designates this live activity for a maximum of 3.0 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \*

### **Nurses**

Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Houston Methodist will provide up to 3.16 contact hours for this activity. Participants must attend each session in its entirety and complete the corresponding items on the evaluation tool. \*

### **Respiratory Care**

This activity has been approved for 3.41 CEUs pending approval by the American Association for Respiratory Care. \*

### **Physical Therapists/Physical Therapist Assistants**

This activity has been approved by the Texas Board of Physical Therapy Examiners for 7.0 total CCUs for PTs and PTAs if attendance is recorded both days. Friday CCUs total 3.5. Saturday CCUs total 3.5.

### **Occupational Therapists**

This activity has been approved for 7.0 hours of OT Education by The Texas Board of Occupational Therapy Examiners if attendance is recorded both days. Friday CCUs total 3.5. Saturday CCUs total 3.5.

### **Speech-Language Pathologists**

This program has been approved for 7.0 clock hours of continuing education credit by the Texas Speech-Language Hearing Association (TSHA) if attendance is recorded both days. Friday CCUs total 3.5. Saturday CCUs total 3.5.

### **Social Workers**

Houston Methodist designates this activity for 3.0 CEUs for the first day, 3.5 CEUs for the second day, and a total 6.5 CEUs if attended both days for social work. This offering complies with section 781.509 of the rules of The Texas State Board of Social Work Examiners [www.bhec.texas.gov](http://www.bhec.texas.gov)

\*CE credits for CME, CNE and RT will **only** be awarded for attending the Health Care Professionals Day Conference on **Friday, October 21, 2022**.

## HOW TO RECEIVE YOUR CERTIFICATE

### **Physicians**

An email will be sent from [learn@houstonmethodist.org](mailto:learn@houstonmethodist.org) with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

*Nurses*

To be awarded up to 3.16 contact hours for this continuing education activity, the participant must:

- Be sure to check in and complete the sign in process
- Attend each session in its entirety (Contact hours are awarded only for full day attendance)
- Complete the evaluation tool. An email will be sent from [learn@houstonmethodist.org](mailto:learn@houstonmethodist.org) with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

*Respiratory Care*

Radiologic Technologists must sign in and attend each session in its entirety. Partial credit will not be awarded.

**DISCLAIMER AND DISCLOSURES**

Houston Methodist makes every effort to develop continuing education activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education and American Nurse Credentialing Center (ANCC), Houston Methodist has implemented a mechanism requiring everyone in a position to control content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers, etc.) to disclose all financial relationships with ineligible companies (companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) and mitigate any relevant financial relationships prior to the activity. Individuals must disclose to participants the existence of financial relationships at the time of the activity and 24 months prior.

Houston Methodist does not view the existence of interests or relationships with ineligible companies as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

In addition, if contributors will be discussing products (drugs/devices) they have been instructed to use generic names and to include various products within and across classes. If at any time during this activity you feel that there has been commercial or promotional bias, please notify the CE coordinator for the activity and note your comments by using the commercial bias comments box in the evaluation form. Please answer the question about balance in the CE activity evaluation candidly.

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.

Faculty members are also asked to disclose any unlabeled use or investigational use (not yet approved for any purpose) or pharmaceutical and medical device products and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

All the relevant financial relationships listed for these individuals have been mitigated.

| Name                     | Role                    | Relevant Financial Relationship(s)   |
|--------------------------|-------------------------|--|
| Ashley Anderson, MD, MPH | Speaker                 | Speaker: Argenx  |
| Amanda Guidon, MD, MPH   | Speaker                 | Consultant: UCB; Consultant: Alexion; Consultant: Argenx; Consultant: Biosensics; Speaker: Oakstone; Researcher: Project Data Sphere |
| Sheetal Shroff, MD       | Co-Director/<br>Speaker | Consultant: Alnylam  |

All other individuals in control of content of this activity have no relevant financial relationships with ineligible companies to disclose.

## EXHIBITORS

We gratefully acknowledge the following companies for  
participating as exhibitors at this activity:

**Accredo**

**Alexion**

**Argenx**

**Immunovant**

**UCB**